Under the agreemnt, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys® platform. Merck is granted a global exclusive license to the ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings Ohtuvayre, a first-in-class COPD drug, into Merck’s portfolio as it looks to ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Strong emotional links between children with chronic conditions and their family caregivers suggest that improving parent well-being may directly benefit a child's overall health and coping mechanisms ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The Global Alcohol-Related Liver Disease Market report for 2025-2035 highlights the escalating trend of alcohol-related liver conditions like alcoholic fatty liver disease (AFLD), alcoholic hepatitis, ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...